Invizius Limited (“Invizius”), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board. Read more…
Munich, 17 October, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO). Gudrun will be responsible for AMSilk’s protein and strain strategy as well as bridging science and business development. With many years of experience in biotechnology research, Gudrun has a […]
Dr. Yang brings extensive experience in leading early-stage clinical trials and late stage global registrational trials London UK / Cambridge, MA USA, 10 October 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, […]
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter, an accomplished global biotech leader with over 25 years of experience across the pharmaceutical value chain, […]
Newly appointed CEO has over 20 years’ experience in company building and strategic business development London UK / Cambridge, MA USA, 25 July 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive […]
